Literature DB >> 8760312

Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine.

H Wen1, R R New, M Muhmut, J H Wang, Y H Wang, J H Zhang, Y M Shao, P S Craig.   

Abstract

Encapsulation of the benzimidazole albendazole in multilamellar liposomes results in a preparation in which this normally insoluble anti-hydatid drug is well solublilized in aqueous media. The high entrapment efficiency observed (75-87%) and the stability of the formulation make this a promising delivery vehicle for improved chemotherapy with albendazole. In particular, the high degree of association with phospholipid may give rise to increased oral bioavailability. Oral administration of albendazole in liposomes led to increased concentration and/or altered metabolism of albendazole sulphoxide (ABZSX) in liver and/or plasma in non-infected Wistar rats. Results from experiments using cotton rats (Sigmodon hispidus) infected with metacestodes of Echinococcus multilocularis show that entrapment within liposomes clearly increases the uptake of albendazole via the oral route. This was reflected by increased levels of albendazole and the two major metabolites in plasma, liver and cyst homogenate when a dose of liposomal albendazole (35 mg/kg) was given orally compared to free albendazole at 50 mg/kg. There was a 75-94% reduction in biomass of the metacestode and a significant increase in survival time for the animals treated with liposome entrapped albendazole. A clear difference in distribution of albendazole and its metabolites in the liver and the metacestode tissues in the presence of cimetidine indicated that the latter has a profound effect on the metabolism of albendazole. There appeared to be a synergistic interaction between albendazole and cimetidine, since the metabolism of albendazole was markedly altered in the combined cimetidine/ liposome-albendazole group, and higher therapeutic effect was observed. These findings indicate potential both for improvement of treatment of larval E. multilocularis infection and for reduction of albendazole dose levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8760312     DOI: 10.1017/s003118200006635x

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  15 in total

1.  Efficacies of albendazole sulfoxide and albendazole sulfone against In vitro-cultivated Echinococcus multilocularis metacestodes.

Authors:  K Ingold; P Bigler; W Thormann; T Cavaliero; B Gottstein; A Hemphill
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Therapeutic efficacy of nanocompounds in the treatment of cystic and alveolar echinococcoses: challenges and future prospects.

Authors:  Nayer Mehdizad Bakhtiar; Abolfazl Akbarzadeh; Adriano Casulli; Mahmoud Mahami-Oskouei; Ehsan Ahmadpour; Sanam Nami; Ali Rostami; Adel Spotin
Journal:  Parasitol Res       Date:  2019-08-11       Impact factor: 2.289

3.  Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.

Authors:  Catherine Devine; Gerard P Brennan; Carlos E Lanusse; Luis I Alvarez; Alan Trudgett; Elizabeth Hoey; Ian Fairweather
Journal:  Parasitol Res       Date:  2010-05-30       Impact factor: 2.289

4.  In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives.

Authors:  Martin Spicher; Carole Roethlisberger; Catharina Lany; Britta Stadelmann; Jennifer Keiser; Luis M Ortega-Mora; Bruno Gottstein; Andrew Hemphill
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

5.  In vitro and in vivo treatments of Echinococcus granulosus with Huaier aqueous extract and albendazole liposome.

Authors:  Hailong Lv; Yufeng Jiang; Min Liao; Hongli Sun; Shijie Zhang; Xinyu Peng
Journal:  Parasitol Res       Date:  2012-09-23       Impact factor: 2.289

6.  Efficiency of liposomal albendazole for the treatment of the patients with complex alveolar echinococcosis: a comparative analysis of CEUS, CT, and PET/CT.

Authors:  Haitao Li; Tao Song; Yongde Qin; Wenya Liu; Xiaohong Li; Yingmei Shao; Hao Wen
Journal:  Parasitol Res       Date:  2015-08-04       Impact factor: 2.289

7.  Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers.

Authors:  I M Rigter; H G Schipper; R P Koopmans; H J M van Kan; H W Frijlink; P A Kager; H-J Guchelaar
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

8.  Improvement of the Bioavailability and Anti-hepatic Alveolar Echinococcosis Effect of Albendazole-Isethionate/Hypromellose Acetate Succinate (HPMC-AS) Complex.

Authors:  Chunhui Hu; Fabin Zhang; Haining Fan
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

9.  Efficacy of Albendazole-Chitosan Microsphere-based Treatment for Alveolar Echinococcosis in Mice.

Authors:  Maitiseyiti Abulaihaiti; Xiang-Wei Wu; Lei Qiao; Hai-Long Lv; Hong-Wei Zhang; Nasrul Aduwayi; Yan-Jie Wang; Xin-Chun Wang; Xin-Yu Peng
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09

10.  Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Lydie Meheus; Vidula Sukhatme; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2014-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.